

August 26, 2024

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

To all stakeholders,

(Amendments) Amendments to “Non-consolidated Summary of Financial Results  
for the First Quarter of the Fiscal Year Ending March 31, 2025”

Perseus Proteomics Inc. (“the Company”) hereby announces amendments to “Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2025” announced on August 14, 2024. The amended parts are underlined.

1. Reasons for amendments

The Company has found some errors in “Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2025” after submission and now makes amendments.

2. Amendment details

(1) Summary

1. Financial Results for the three months ended June 30, 2024 (April 1, 2024 – June 30, 2024)

(1) Operating results

(Before amendment)

|                                     | Basic earnings<br>per share | Diluted earnings<br>per share |
|-------------------------------------|-----------------------------|-------------------------------|
| Three months ended<br>June 30, 2024 | yen<br><u>(15.79)</u>       | yen<br>-                      |
| June 30, 2023                       | (35.90)                     | -                             |

(After amendment)

|                                     | Basic earnings<br>per share | Diluted earnings<br>per share |
|-------------------------------------|-----------------------------|-------------------------------|
| Three months ended<br>June 30, 2024 | yen<br><u>(17.05)</u>       | yen<br>-                      |
| June 30, 2023                       | (35.90)                     | -                             |

(2) Summary

Notes

(3) Number of issued shares (common shares)

(iii) Average number of shares outstanding during the period

(Before amendment)

As of June 30, 2024: 13,884,413 shares

(After amendment)

As of June 30, 2024: 12,855,146 shares

END